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virus (HCV) infection. Treatments in Japan are currently limited to
interferon-alfa–based regimens, which are associated with tolerability
and efﬁcacy issues. A novel regimen combining two oral HCV
therapies, daclatasvir and asunaprevir (DCV þ ASV), has shown
favorable results in Japanese patients with chronic genotype 1b HCV
infection. Comparisons of clinical and economic outcomes associated
with DCV þ ASV treatment and current standards of care were
investigated. Methods: The MOdelling the NAtural histoRy and
Cost-effectiveness of Hepatitis cost-effectiveness model projected
outcomes in 1000 patients aged 70 years with either chronic hepatitis
C or compensated cirrhosis over a lifetime simulation. Japanese-
speciﬁc disease transition rates were used, and discounting was
applied annually at a rate of 2%. Efﬁcacy data for DCV þ ASV and
telaprevir triple therapy (telaprevir þ pegylated interferon-alfa þ
ribavirin [TVR þ pegIFN-α/RBV]) were obtained from a Japanese
subgroup analysis found within a global meta-analysis: sustained
virological response rates of 74%, 85%, and 87% were reported for null
responders (NRs), partial responders (PRs), and interferon-alfa–ineli-
gible/intolerant patients, respectively, treated with DCV þ ASV, and
rates of 42% and 59% were reported for NRs and PRs, respectively,ee front matter Copyright & 2014, International S
r Inc.
1016/j.vhri.2014.04.005
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pondence to: Thomas Ward, Health Economicstreated with TVR þ pegIFN-α/RBV. Results: Initiating DCV þ ASV
treatment in patients in the chronic hepatitis C disease stage resulted
in quality-adjusted life-year gains of 0.96 and 0.77 over TVR þ pegIFN-
α/RBV for NRs and PRs, respectively, and a gain of 2.61 in interferon-
alfa–ineligible/intolerant patients over no treatment. Similarly,
quality-adjusted life-year gains of 1.11, 0.90, and 3.05 were observed
when initiating treatment in patients in the compensated cirrhosis
stage. Cumulative lifetime events of decompensated cirrhosis,
hepatocellular carcinoma, and liver-related mortality were reduced
by up to 66, 115, and 128, respectively, with DCV þ ASV treatment.
Conclusions: There is a lack of successful therapies for patients with
HCV who have previously failed to achieve sustained virological
response or are ineligible for interferon-alfa–based therapies. Results
demonstrate that the provision of an alternative, interferon-alfa–free
regimen, such as DCV þ ASV, offers signiﬁcant value in terms of
avoiding life-threatening liver complications and increasing patients’
quality of life.
Keywords: asunaprevir, clinical effectiveness, daclatasvir, hepatitis C.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The global burden of the hepatitis C virus (HCV) is signiﬁcant,
with an estimated 3% of the world’s population chronically
infected [1]. Japan has one of the highest endemic rates of HCV
infection; approximately 2 million people are infected, predom-
inately with genotype 1b, resulting in more than 30,000 liver-
related deaths each year [2–4]. An interferon-alfa–based treat-
ment regimen is the mainstay of therapy for HCV-infected
individuals [5], with the aim of eradicating the infection and
thereby preventing disease progression. The recognized clinicalend point for HCV eradication is sustained virological response
(SVR), and recent advances have given rise to SVR rates of the
order of 70% in treatment-naive patients, using a triple therapy
regimen consisting of pegylated interferon-alfa, ribavirin, and a
protease inhibitor (e.g., telaprevir or boceprevir [6,7]). Interferon-
alfa–based regimens, however, are associated with tolerability
issues; adverse events commonly observed include anemia,
pyrexia, rash, renal toxicity, and gastrointestinal-related disor-
ders [8,9], and there remains a proportion of patients who do not
achieve SVR, particularly if they are previous nonresponders. For
those patients intolerant of or ineligible for interferon-alfa–basedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
icted grant from Bristol-Myers Squibb.
and Outcomes Research Ltd., Singleton Court Business Park,
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Fig. 1 – Flow diagram of the MONARCH model. CC,
compensated cirrhosis; CHC, chronic hepatitis C; DC,
decompensated cirrhosis; HCC, hepatocellular carcinoma;
MONARCH, MOdelling the NAtural histoRy and Cost-
effectiveness of Hepatitis; SVR, sustained virological
response.
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they remain at risk of developing life-threatening complications
including decompensated cirrhosis (DC) and hepatocellular
carcinoma (HCC).
An interferon-alfa–free, all-oral regimen comprising daclatasvir
and asunaprevir has been investigated for the treatment of patients
with HCV genotype 1b infection [10]. Both daclatasvir and asunap-
revir have demonstrated robust antiviral activity, with no clinically
meaningful pharmacokinetic interactions when coadministered
[11]. This regimen presents a signiﬁcant step forward in the treat-
ment of HCV infection for both untreated patients and those
intolerant of or ineligible for interferon-alfa–based regimens. Dacla-
tasvir is a ﬁrst-in-class NS5A replication complex inhibitor with
potent pan-genotypic antiviral activity in vitro (HCV genotypes 1–6)
[12], and asunaprevir is a selective NS3 protease inhibitor with
antiviral activity against HCV genotypes 1, 4, 5, and 6 in vitro [13].
This study aimed to model the lifetime clinical and economic
outcomes associated with the use of daclatasvir combined with
asunaprevir (DCV þ ASV) for the treatment of patients with
chronic HCV genotype 1b infection, speciﬁcally in a Japanese
setting, who are either intolerant of or ineligible for interferon-
alfa–based therapies, and those who did not respond to previous
interferon-alfa–based treatment. Comparisons against current
treatment options were made: telaprevir combined with pegy-
lated interferon-alfa and ribavirin (TVR þ pegIFN-α/RBV), pegy-
lated interferon-alfa and ribavirin (pegIFN-α/RBV), and no
treatment. Because of the relative lack of data associated with
DCV þ ASV treatment, sensitivity analyses were performed using
efﬁcacy rates derived from a global meta-analysis, with the
intention of gaining a broader perspective of how DCV þ ASV
might perform in the clinical setting.Table 1 – Disease transition rates.
Transition (genotype 1b) Mean (SE) Source
CHC to CC 0.065 (0.011) Nakamura et al.
[23]
CHC to HCC 0.016 (0.004) Nakamura et al.
[23]
CC to DC 0.021 (0.006) Imazeki et al.
[24]
CC to HCC 0.043 (0.008) Hayashida et al.
[25]
DC to HCC 0.083 (0.022) Nakamura et al.
[23]
DC to death 0.153 (0.017) Nakamura et al.
[23]
HCC to death 0.200 (0.012) Nakamura et al.
[23]
CC SVR to HCC 0.018 (0.011) Arase et al.
[26]
CC, compensated cirrhosis; CHC, chronic hepatitis C; DC, decom-
pensated cirrhosis; HCC, hepatocellular carcinoma; SE,
standard error.Methods
Model
The objective of this study was to compare the long-term clinical
and economic outcomes of DCV þ ASV with the current standard
of care for chronic HCV genotype 1b infection in Japan. A model-
ing analysis was performed to predict the lifetime clinical and
economic outcomes associated with DCV þ ASV treatment using
a previously published and validated computer cohort simulation
model [14]. The model used (the MOdelling the NAtural histoRy
and Cost-effectiveness of Hepatitis [MONARCH] model) is a
cohort-based Markov lifetime simulation created in Microsoft
Excel and designed to model the natural history of HCV and its
complications [14–16]. The model runs in annual cycles over a
variable time horizon, up to patient lifetime (80 years from start).
Cohorts of 1000 patients are deﬁned and enter the model at either
the chronic hepatitis C (CHC) or the compensated cirrhosis (CC)
disease stage. From here, those with CHC can progress to CC and
all patients can progress to DC, HCC, death, or a state of SVR. The
MONARCH model ﬂow diagram is presented in Figure. 1. The
model outputs total costs, incidence of clinical events, quality-
adjusted life-years (QALYs), and life expectancy. Costs, QALYs,
and life-years were all discounted at a rate of 2%, in line with
current Japanese guidelines.
Disease transition rates are applied annually to the prevalent
population in each health state to model the natural history of
HCV. Patients who achieve SVR from the state of CHC remain in
the state of SVR for the duration of the simulation, whereas those
who achieve SVR from the state of CC may relapse and progress
to HCC. In those subjects failing to respond to treatment, CHC
progression continues from whichever disease stage they were in
at initiation of antiviral therapy. All transition rates are drawn
from recently published literature speciﬁc to the Japanese setting.All-cause mortality is incorporated into the model via the use of
Japanese-speciﬁc abridged life tables and affects patients in the
CHC, CC, and SVR Markov states. The transition rates used in the
model are presented in Table 1.
Health states within the model are subject to speciﬁc cost and
utility values, applied annually. Health state utility values were
obtained from the literature. To estimate health state costs, 10
Japanese hepatologists were surveyed between March 2013 and
May 2013. Information regarding the treatment of CHC and CC in
clinical practice was collected, including the treatments used,
clinical tests, frequency of examinations, and adverse events.
This information was then pooled and translated into costs; unit
prices for disease management, clinical tests performed, and
treatments prescribed were derived from the medical service fee
or National Health Insurance price list. All costs and health utility
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Table 2.
Therapy-speciﬁc efﬁcacy data are applied to the cohort to
determine the distribution of patients among CHC, CC, and SVR
health states after treatment initiation. Each therapy uses a
course of antiviral treatment. The duration of antiviral consump-
tion differs depending on the drugs used and affects the adverse-
event proﬁle associated with each treatment. Efﬁcacy data
sources for this study are described below. It is assumed that
all patients complete treatment.
The costs associated with adverse events are modeled as a per-
event cost. Each patient who suffers an adverse event is assumed
to incur a cost that relates to the duration of his or her respective
treatment. Only rash and anemia are modeled; it is assumed that
all other adverse events would either not incur an additional cost
or would occur too infrequently to affect the results substantially.
The weekly costs of rash and anemia used (¥2,634.08 and
¥2,135.63, respectively) were derived from the hepatologist survey
and National Health Insurance costs, assuming an average dura-
tion of 24 weeks, the same duration as therapy with pegIFN-α/RBV.
Analysis Plan
Using Japanese-speciﬁc disease progression rates, the natural
history of HCV infection in cohorts of 1000 patients aged 70 years
was modeled; 50% of the cohort members were female. Patients
were simulated until death, and the predicted clinical outcomes
and costs were recorded. Results for DCV þ ASV were compared
with simulations of treatment with TVR þ pegIFN-α/RBV, pegIFN-
α/RBV, and no treatment to quantify the potential beneﬁt of DCV
þ ASV antiviral therapy. The base-case analysis incorporated the
following:1.T
H
S
S
C
C
C
C
D
H
D
C
s
*
†Previous interferon-alfa–based therapy null responders
a. DCV þ ASV versus TVR þ pegIFN-α/RBV
b. DCV þ ASV versus pegIFN-α/RBV
c. DCV þ ASV versus no treatmentab
ea
VR
VR
HC
HC
C m
C c
C
CC
eat
C, c
usta
CHC
CH2. Previous interferon-alfa–based therapy partial responders
a. DCV þ ASV versus TVR þ pegIFN-α/RBV
b. DCV þ ASV versus pegIFN-α/RBV
c. DCV þ ASV versus no treatment3. Pegylated interferon-alfa–intolerant/ineligible patients
a. DCV þ ASV versus no treatmentNull response was deﬁned as a decrease in HCV RNA by at least 2
log by week 12 but detectable HCV RNA during the therapy period.le 2 – Health state costs and utilities.
lth state Mean cost (¥) (SE) S
CHC (ﬁrst year only) 57,186 (8,515) Japanese he
CC (ﬁrst year only) 124,439 (33,346) Japanese he
monitoring* 119,227 (8,851) Japanese he
care† 97,610 (21,817) Japanese he
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ompensated cirrhosis; CHC, chronic hepatitis C; DC, decompensate
ined virological response.
/CC monitoring refers to costs including inpatient/outpatient care
C/CC care refers to costs including hepatoprotective medication, nuPartial response was deﬁned as a reduction of 2 log or more from
baseline in HCV RNA but never achieving undetectable HCV RNA
after at least 12 weeks. Pegylated interferon-alfa–intolerant/ineligible
patients include those who previously discontinued interferon-alfa–
based therapy because of an adverse reaction or have a contra-
indication, and are therefore naive to interferon-alfa–based therapy.
A sensitivity analysis using results from a global meta-
analysis was undertaken to provide insight into the potential
variation in treatment effects.
Data Sources and Assumptions
Base-case analysis
For the base-case analysis, Japanese-speciﬁc results were taken
from a previously undertaken global meta-analysis, in which a
subgroup analysis of Japan-only studies was incorporated [17,18].
A recent phase 3 clinical trial for DCV þ ASV undertaken in
Japanese patients with chronic HCV genotype 1b infection
(AI447026, NCT01497834) was incorporated within the meta-
analysis. Results from this trial were incorporated in the base-
case analysis to provide an insight into the clinical effectiveness
of DCV þ ASV in an interferon-alfa–ineligible and intolerant
cohort, which was not part of the meta-analysis. Treatment-
related effects are reported in Table 3.
DCV þ ASV phase 3 clinical trial
AI447026 included two parallel populations: prior nonresponder
(null and partial responders; n ¼ 87) and interferon-alfa–intoler-
ant/ineligible (n ¼ 135) [10]. All subjects were administered 60 mg
of daclatasvir once daily and 100 mg of asunaprevir twice daily
for 24 weeks and followed for 24 weeks after the last dose of
study drug. The primary efﬁcacy end point was the proportion of
subjects with SVR24, deﬁned as HCV RNA below the lower limit of
quantitation (o15 IU/mL) target detected or not detected at
follow-up week 24 for each population. Safety was assessed as
a secondary end point.
Meta-analysis and Japanese-speciﬁc subgroup analysis
The meta-analysis was performed to determine the relative
efﬁcacy and safety of different HCV treatment regimens used
worldwide [17,18]. Trials investigating the treatment of adults
with CHC, regardless of HCV genotype, who were either naive to
treatment or had been previously treated with an interferon-alfa–
based therapy, were included. Relevant articles published in the
year 2000 or later were identiﬁed through searches of the PubMedource Mean utility (SE) Source
patologist survey 0.960 (0.082) Ishida et al. [27]
patologist survey 0.960 (0.082) Ishida et al. [27]
patologist survey 0.920 (0.078) Ishida et al. [27]
patologist survey
patologist survey 0.860 (0.037) Okida [28]
patologist survey
patologist survey 0.670 (0.057) Okida [28]
ura et al. [23] 0.380 (0.032) Ishida et al. [3]
ssumed 0.000 (0.000) Assumed
d cirrhosis; HCC, hepatocellular carcinoma; SE, standard error; SVR,
and tests required.
tritional therapy, and other medication required.
Table 3 – Base-case treatment-related outcomes: Mean (SE).
Regimen Duration
(wk)
Population Japanese-speciﬁc subgroup of
global meta-analysis
Source
SVR24 Rash
incidence
Anemia
incidence
DCV þ ASV 24 Treatment-intolerant/
ineligible*
0.874 (0.029) 0.046 (0.022) 0.011 (0.011) 026 phase 3 clinical
trial data [10]
Broglio et al. [17,18]
Previous null responder 0.740 (0.097) 0.050 (0.046) 0.020 (0.036) Broglio et al. [17,18]
Previous partial
responder
0.850 (0.071) 0.050 (0.046) 0.020 (0.036) Broglio et al. [17,18]
TVR þ pegIFN-
α/RBV
12† Previous null responder 0.420 (0.074) 0.280 (0.084) 0.580 (0.148) Broglio et al. [17,18]
Previous partial
responder
0.590 (0.082) 0.280 (0.084) 0.580 (0.148) Broglio et al. [17,18]
PegIFN-α/RBV 48 Previous null responder 0.080 (0.026) 0.160 (0.066) 0.380 (0.143) Broglio et al. [17,18]
Previous partial
responder
0.140 (0.048) 0.160 (0.066) 0.380 (0.143) Broglio et al. [17,18]
DCV þ ASV, daclatasvir þ asunaprevir; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SE, standard error; SVR, sustained virological
response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin.
* Adverse-event data were taken directly from the data tables provided within the meta-analysis relating to the DCV þ ASV trial, and SVR rates
were taken directly from the trial itself.
† Combined with 24 wk of pegIFN-α/RBV.
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single-arm or randomized clinical trials of TVR þ pegIFN-α/RBV
were included. The primary efﬁcacy outcome measure was SVR
24 weeks following the completion of treatment (SVR24). A total of
58 studies were included in the meta-analysis; among these, ﬁve
were conducted in Japan and included in the Japanese-speciﬁc
subgroup analysis.
The meta-analysis was performed with a Bayesian hierarchical
model. The foundational treatment was set as pegIFN-α/RBV and, for
each end point, the response rate of pegIFN-α/RBV was allowed to
vary from study to study; however, the odds ratio between each pair
of treatments was assumed to be constant across studies, condi-
tional on covariates and treatment arms. Each study was assumed
to be sampled from a larger population of studies. The log odds of
response for pegIFN-α/RBV in study s was modeled as follows:
αs¼ log
Po,s
1-Po,s
 
where Pt,s is the probability of response for treatment t in study s.
Study-level effects are modeled with a distribution of αs 
Nðμα, τ2αÞ using the following weak hyper priors:
μα  N(0,102) and τ2α¼Inverse Gammað0:5,0:001Þ
The data are allowed to shape the amount of variability across
studies and, because of the hyper priors carrying little prior
information, the amount of heterogeneity between studies is
also largely determined by the data. The log-odds of response to a
treatment is as follows:
logð□Þ Pt,s
1Pt,s
 
¼αsþθtþβZ
for t ¼ 0, 1, …, 4
The θ’s represent treatment effects. For pegIFN-α/RBV, the
treatment effect is assumed to be 0, allowing αs to be identiﬁed as
the pegIFN-α/RBV log-odds for study s, while the treatment
effects for TVR þ pegIFN-α/RBV and DCV þ ASV are modeled
independently with “ﬂat” prior distributions N(0,102).
The following covariates (denoted by Z) were incorporated in
the analysis of SVR24 rates: Treatment history (whether patients are treatment-naive,
prior null or partial responders, or have had a relapse orbreakthrough response to previous pegIFN-α/RBV treatment);
 HIV coinfection;
 HCV genotype (1a, 1b, 2 or 3 [grouped], 4);
 Country (Japan or outside Japan); and
 Interaction term between previously treated with pegIFN-α/
RBV and the relevant therapy.
 The following covariates were incorporated in the analysis of
adverse events:
 Treatment history (treatment-naive or previously treated);
 HIV coinfection; and
 HCV genotype (1 vs. not).
The β’s represent covariate effects and are modeled independ-
ently with “ﬂat” prior distributions N(0,102). Posterior distribu-
tions for the terms in the model were computed and, on the basis
of these, posterior mean odds ratios for response with DCV þ ASV
therapy versus other therapies were calculated.
The Japanese-speciﬁc subgroup meta-analysis for SVR24 mod-
eled the effects of the covariates using all studies (58 studies
globally) and all populations, as in the global meta-analysis, but
the estimates of the efﬁcacy of the therapies in Japanese patients
uses only the Japanese trials (ﬁve trials conducted in Japan). This
modeling creates common effects of the covariates, but com-
pletely separate effects for a treatment arm, depending on
country (Japan vs. outside Japan). Of the ﬁve studies conducted
in Japan, safety/tolerability end points were available from the
extracted populations or treatment arms for only three of these
studies. Because of sparse data, formal modeling of the safety
and tolerability end points for the Japan subgroup was not
performed; thus, although adverse-event rates applied in the
model are therapy-speciﬁc, they remain constant across
analyses.Sensitivity analysis
Because data regarding the effectiveness of DCV þ ASV are
relatively few, sensitivity analyses were undertaken around the
base case to provide some insight into the potential effect on
outcomes with varying efﬁcacy. Patients with chronic HCV
infection were modeled. Results from the full data set of the
Table 4 – Results of base-case analysis for patients with chronic HCV (N ¼ 1,000).
Outcome DCV þ ASV TVR þ pegIFN-α/RBV PegIFN-α/RBV No treatment
Null
responder
Partial
responder
Ineligible/
intolerant
Null
responder
Partial
responder
Null
responder
Partial
responder
Null
responder
Partial
responder
Ineligible/
intolerant
Number achieving SVR 740 850 874 420 590 80 140 0
Per-patient QALYs 13.03 13.35 13.43 12.07 12.58 11.05 11.23 10.82
Per-patient life-years 13.99 14.16 14.20 13.49 13.76 12.96 13.06 12.84
Additional per-patient
cost of complication
management compared
with DCV þ ASV
NA NA NA 1,975,431 1,613,146 4,040,136 4,342,040 4,463,999 5,128,189 5,273,817
Total observed clinical events
CC 147 85 71 328 232 520 486 565
DC 24 14 12 53 38 85 79 92
HCC 93 54 45 208 147 330 308 359
LM 104 60 50 232 164 368 344 400
Numbers needed to treat to avoid one event when using DCV þ ASV
CC NA NA NA 6 7 3 2 2 2 2
DC NA NA NA 34 42 16 15 15 13 12
HCC NA NA NA 9 11 4 4 4 3 3
LM NA NA NA 8 10 4 4 3 3 3
CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LM, liver-related mortality; NA, not
applicable; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin; QALY, quality-
adjusted life-year.
Notes: Costs and QALYs are presented on a per-patient level. Comparisons of cost differences and numbers needed to treat are made against appropriate comparators, for example, DCV þ ASV:
Null responders are compared only with other null responder cohorts (or the no treatment cohort).
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Table 5 – Results of base-case analysis for patients with compensated cirrhosis (N ¼ 1,000).
Outcome DCV þ ASV TVR þ pegIFN-α/RBV PegIFN-α/RBV No treatment
Null
responder
Partial
responder
Ineligible/
intolerant
Null
responder
Partial
responder
Null
responder
Partial
responder
Null
responder
Partial
responder
Ineligible/
intolerant
Number achieving SVR 740 850 874 420 590 80 140 0
Per-patient QALYs 11.21 11.59 11.68 10.10 10.69 8.91 9.12 8.63
Per-patient life-years 12.75 12.96 13.01 12.11 12.45 11.43 11.55 11.27
Additional per-patient cost
of complication
management compared
with DCV þ ASV
NA NA NA 1,949,966 1,592,455 3,987,613 4,285,538 4,405,110 5,060,546 5,204,264
Total observed clinical events
DC 54 31 26 120 85 190 178 207
HCC 322 296 290 396 357 476 462 494
LM 345 305 296 461 399 584 562 613
Numbers needed to treat to avoid one event when using DCV þ ASV
DC NA NA NA 15 19 7 7 7 6 6
HCC NA NA NA 13 16 6 3 6 2 5
LM NA NA NA 9 11 4 2 4 2 3
DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; LM, liver-related mortality; NA, not applicable; pegIFN-α/RBV, pegylated interferon-alfa þ
ribavirin; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin; QALY, quality-adjusted life-year.
Notes: Costs and QALYs are presented on a per-patient level. Comparisons of cost differences and numbers needed to treat are made against appropriate comparators, for example, DCV þ ASV:
Null responders are compared only with other null responder cohorts (or the no treatment cohort).
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Fig. 2 – Estimated cumulative incidence of end-stage liver disease complications (base-case analysis). CC, compensated
cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; LM, liver-
related mortality; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 3 6 – 1 4 5142global meta-analysis were used to provide additional insight into
the effects of treatment among null and partial responders.
Efﬁcacy (SVR24) and safety (rate of anemia and rash) data used
in both the base-case and sensitivity analysis are included in
Table 4.Model assumptions1. If a patient achieves SVR from chronic HCV, he or she remains
in a state of SVR and cannot progress to end-stage liver
disease complications.2. Liver transplant is not considered as a treatment option/
disease state because of it not being possible or appropriate
for most patients in Japan [3].3. No patients discontinue therapy.
4. No therapy-related QALY decrements are applied to patients
when receiving treatment because of a lack of consistent
information.5. Efﬁcacy rates remain constant across CHC and CC disease
stages.6. Therapy costs are not modeled because of the costs of
daclatasvir and asunaprevir not being published.
Results
Base Case
The base-case analysis suggested that DCV þ ASV is superior to
TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment in terms of
clinical outcomes, reductions in cost, and total health beneﬁt forpatients receiving treatment from both the CHC and CC disease
states (Tables 4 and 5). Treatment with DCV þ ASV in patients
with CHC who previously had a null response was associated
with an increased number of QALYs per patient: 13.03, compared
with 12.07, 11.05, and 10.82 when treated with TVR þ pegIFN-α/
RBV, pegIFN-α/RBV, and no treatment, respectively. Among pre-
vious partial responders and interferon-alfa–ineligible/intolerant
patients, total per-patient QALYs of 13.35 and 13.43 were
observed when treated with DCV þ ASV, compared with 12.58,
11.23, and 10.82 among partial responders when using TVR þ
pegIFN-α/RBV, pegIFN-α/RBV, and no treatment regimens, respec-
tively, and 10.82 among interferon-alfa–ineligible/intolerant
patients who receive no treatment. Furthermore, treating
patients with CC resulted in increased relative per-patient QALY
gains when initiating therapy with DCV þ ASV therapy, yielding
increases of up to 1.11, 2.47, and 3.05 when compared with TVR þ
pegIFN-α/RBV, pegIFN-α/RBV, and no treatment, respectively.
Because of the higher efﬁcacy seen with DCV þ ASV, the
lifetime risk of CC, DC, HCC, and liver-related mortality was
greatly reduced in this treatment arm. Null responders incurred a
reduced relative risk of 55.17% and 18.84% to 55.17% when treated
with DCV þ ASV from the CHC and CC disease stage, respectively,
compared with TVR þ pegIFN-α/RBV, while relative risk reduc-
tions of 63.41% and 17.01% to 63.41%, respectively, were observed
in the partial responder cohort when compared with no treat-
ment. The greatest reduction was observed among ineligible/
intolerant patients. These relative risk reductions resulted in a
signiﬁcantly lower cost of end-stage liver disease complication
management: up to ¥1,975,431 less in null responders and
¥1,613,146 less in partial responders compared with TVR þ
pegIFN-α/RBV and ¥5,273,817 less in interferon-alfa–ineligible/
Table 6 – Sensitivity analysis of patients with chronic HCV (N ¼ 1,000).
Population Results of global meta-analysis: Mean (SE) Analysis
SVR24 Rash
incidence
Anemia
incidence
Source Per-
patient
QALYs
Additional per-
patient cost of
complication
management
compared
with DCV þ ASV
Total events
CC DC HCC Liver
mortality
DCV þ ASV: Previous
null responder
0.670 (0.120) 0.080 (0.066) 0.010 (0.013) Broglio et al.
[17,18]
12.82 NA 186 30 118 132
DCV þ ASV: Previous
partial responder
0.790 (0.092) 0.080 (0.066) 0.010 (0.013) Broglio et al.
[17,18]
13.17 NA 119 19 75 84
TVR þ pegIFN-α/RBV:
Previous null
responder
0.390 (0.074) 0.350 (0.071) 0.310 (0.099) Broglio et al.
[17,18]
11.98 1,723,110 345 56 219 244
TVR þ pegIFN-α/RBV:
Previous partial
responder
0.550 (0.066) 0.350 (0.071) 0.310 (0.099) Broglio et al.
[17,18]
12.46 1,481,587 254 41 161 180
PegIFN-α/RBV: Previous
null responder
0.050 (0.013) 0.200 (0.054) 0.160 (0.066) Broglio et al.
[17,18]
10.96 3,779,734 537 87 341 380
PegIFN-α/RBV: Previous
partial responder
0.090 (0.026) 0.200 (0.054) 0.160 (0.066) Broglio et al.
[17,18]
11.08 4,262,781 514 84 326 364
CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; NA, not applicable; pegIFN-α/RBV,
pegylated interferon-alfa þ ribavirin; SE, standard error; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin.
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presents a graphical interpretation of the cumulative incidence
of end-stage liver events of the lifetime of a cohort of patients
treated in the CHC stage of HCV and further demonstrates the
signiﬁcance of the observed event reductions associated with
DCV þ ASV.
Sensitivity Analysis
When using data from the global meta-analysis, similar results to
the base-case analysis were observed (Table 6). DCV þ ASV was
still associated with fewer end-stage liver complications com-
pared with all alternative therapies. The relative risk reductions
of end-stage liver complications were 45.90% for null responders
and 53.33% for partial responders treated in the CHC disease
stage, when compared with treatment with TVR þ pegIFN-α/RBV.
Furthermore, treatment with DCV þ ASV was associated with
QALY gains of between 0.71 and 0.84 over treatment with TVR þ
pegIFN-α/RBV and gains of between 1.86 and 2.09 over pegIFN-α/
RBV. Complication cost reductions of between ¥1,481,587 and
¥4,262,781 were observed when using DCV þ ASV therapy. Over-
all, the sensitivity analysis reported results consistent with those
of the base-case analysis.Discussion
In modeling lifetime events associated with the use of different
treatment strategies in hard-to-treat patients speciﬁc to the
Japanese setting, results suggested that DCV þ ASV is superior
to TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment in terms
of clinical outcomes, reductions in complication management
costs, and total health beneﬁt. This is reﬂected in increased QALY
gains and reductions in end-stage liver disease complication
incidence rates for DCV þ ASV over treatment regimens reﬂective
of the current standard of care. A conclusion of the global meta-
analysis was that there is a 98.1% probability that DCV þ ASV is
superior to TVR þ pegIFN-α/RBV among previously treated
patients [17,18]; therefore, the validity of the results obtained
within this analysis further support the previously demonstrated
claims of clinical superiority. Furthermore, it is likely that the
beneﬁt of treatment with DCV þ ASV has been underestimated
because of conservative estimates of SVR used in this study. A
recent phase 3 trial in Japanese patients reported SVR rates of
90.9% and 91.9% in cirrhotic and elderly patients (Z65 years),
respectively [10].
There are difﬁculties in comparing outcome data across treat-
ment regimens because of the lack of head-to-head trials per-
formed in hepatitis C research. In the absence of direct
comparisons, mixed-treatment and indirect comparative data
can provide a useful perspective, but have inherent limitations.
Because studies incorporated into the Japanese subgroup of the
meta-analyses were limited and it was uncertain how well this
would relate to real-world observations in clinical practice,
comparisons of the outcomes observed in the broader, global
meta-analysis were carried out. When using the global meta-
analysis data, the sensitivity analysis produced similar results to
those seen in the base case; similarly, when using individual trial
data for DCV þ ASV and TVR þ pegIFN-α/RBV interferon-alfa–
ineligible and intolerant patients, DCV þ ASV was favorable in
terms of complication event rates, QALYs, and complication cost
outcomes.
SVR is a clinically meaningful end point in the treatment of
HCV, and a high rate of SVR observed in clinical trials of DCV þ
ASV translates into a reduction in life-threatening complication
rates compared with standard of care in difﬁcult-to-treat
patients. For patients treated in the CC stage, the observedincidence of HCC and resultantly liver mortality are elevated
over those treated in CHC. This is due to these patients being in a
more severe disease state on initiating treatment, and only these
patients may still progress to HCC and liver mortality following
SVR; those in CHC state do not. Lower estimates of transition to
HCC in patients who have achieved SVR from the CC stage have
been reported consistently [19–22]; however, in this analysis, a
rate more reﬂective of real-world disease progression in Japan
was adopted.
Tolerability, with regard to rates of rash and anemia,
two signiﬁcant adverse events observed with current treatment
regimens, is greatly improved when using DCV þ ASV. Toler-
ability has an inherent effect on uptake and adherence, as well as
on the quality of life in those undergoing treatment. These
factors have the potential to signiﬁcantly affect economic anal-
yses and, subsequently, inﬂuence public health decisions.
Furthermore, higher rates of SVR within a population could
have an effect on disease transmission, an important consider-
ation in a country with one of the highest endemic rates of
infection.
Treatment options available to Japanese patients are currently
limited to interferon-alfa–based regimens. Where a patient is
unable to receive or has previously not responded to interferon-
alfa–based therapy, they do not currently have an alternative for
treatment; in these patients, progression to life-threatening
complications of HCV infection is likely. Conditional on the
modeling assumptions applied, this study shows that the provi-
sion of an alternative, interferon-alfa–free regimen, such as DCV
þ ASV, could offer valuable beneﬁt in terms of avoiding life-
threatening liver complications and increasing patients’ quality
of life.
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